Clinical Trials Logo

Clinical Trial Summary

The investigators aim to optimize the radiation treatment of early stage lung cancer patients. Therefore, detailed understanding is needed of the type of toxicity and the location of these toxicities for patients who receive high fraction doses. These have not been measured in these patients before, therefore our primary research question is: is it possible to measure changes in cardiac condition after radiotherapy, with respect to cardiac arrhythmias, fibrosis, hemodynamic function change and pericarditis?


Clinical Trial Description

Rationale: For lung cancer patients that receive thoracic irradiation, cardiac toxicity was not considered to play a role, because it was expected to occur many years after treatment. However, recently several studies have shown higher death rates for lung cancer patients receiving higher cardiac doses, possibly due to cardiac toxicity. Most knowledge on cardiac toxicity that is available, is based on patients that receive conventionally fractionated radiation treatment, where the heart receives a relatively low dose of radiation. For patients that receive stereotactic body radiation therapy (SBRT), which gives high fraction doses, the heart may receive peak doses of radiation, especially for centrally located lung tumours. This type of therapy is standard of care for early stage lung cancer patients, with very high local control that is similar to surgically treated patients. In order to improve the radiation treatment for these early stage lung cancer patients, detailed knowledge on cardiac toxicity in these patients is necessary. Objective: the investigators aim to optimize the radiation treatment of early stage lung cancer patients. To reach that goal, detailed understanding is needed of the type of toxicity and the location on the heart of these toxicities for patients who receive high fraction doses. These have not been measured in this category of patients before, therefore our primary research question is: is it possible to measure changes in cardiac condition 3 or 12 months after radiotherapy, with respect to cardiac arrhythmias, tissue fibrosis, hemodynamic function change and pericarditis? Our secondary research question is: is it possible to measure local fibrosis and correlate this to local dose? The third research question is: is it possible to measure early cardiac morphology changes during the course of the irradiation? Study design: Twenty five patients with early stage lung cancer or a solitary lung metastasis of a solid tumour, who are treated with SBRT will be enrolled in an observational prospective cohort study and treated following standard clinical practice on a cone-beam or MR guided linear accelerator (Linac). Condition of the heart will be examined before treatment using ECG, cardiac MRI with added T1- and T2-mapping, echocardiography and blood biomarkers. These tests will be repeated 3 and 12 months after treatment. Study population: 25 patients with a lung tumour in close proximity to the heart (edge of tumour <3cm from the heart) will be included. All patients receive SBRT for a primary lung tumour (stage IA-IIB), or for a solitary lung metastasis of a solid tumour. Intervention (if applicable): not applicable Main study parameters/endpoints: It will be investigated 1) if changes in cardiac condition (cardiac arrhythmias, fibrosis, hemodynamic function change and pericarditis) can be visualised and quantified. A negative change of more than 5% between pre-and post-treatment measurements is considered toxicity. 2) If local fibrosis is associated to local dose, 3) if morphology changes are visible during treatment. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The patient will have 3 sessions with several diagnostic tests: ECGs, cardiac MRIs, echocardiography and blood sampling, and will fill out 3 questionnaires. Limited side effects of these tests are expected. Cardiac tests will be evaluated by a cardiologist and dedicated radiologist and reported to the radiation oncologist who will inform the patient and refer to the cardiologist if needed. The burden for these patients will be, next to the time spent for the diagnostic tests and travel time; an intravenous blood sampling and administration of MRI contrast agent. The additional time spent for diagnostic tests per session are: echo (30 min), ECG (5 min), vena puncture (5 min) and MRI (45 min) + time in the waiting room. Filling out the 3 questionnaires will take 15 min each. The possible benefit for the patient is the extensive cardiac screening. Should a problem come to light, the patient will be referred to the cardiologist. Results from this patient cohort are directly relatable to all early stage NSCLC who are treated with SBRT, and possibly oesophageal cancer patients as well. Should this study show that cardiac dose causes cardiac toxicity in this time frame, the aim should be to improve treatment for all patients who are comparable. Ergo, patients who receive cardiac dose because of their tumour location, and who are generally unfit for surgery because of their physical condition (early stage NSCLC patients and oesophageal cancer patients). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03984019
Study type Interventional
Source The Netherlands Cancer Institute
Contact
Status Terminated
Phase N/A
Start date January 13, 2021
Completion date April 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Recruiting NCT06145048 - Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. Phase 2
Recruiting NCT05375591 - AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer
Recruiting NCT04684186 - Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy in Lung Cancer
Completed NCT00528645 - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT03944798 - Surveillance AFter Extremity Tumor surgerY N/A
Recruiting NCT04940936 - Shared Decision Making on Radiation Dose for Lung Malignancies N/A
Recruiting NCT04455438 - SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions N/A
Completed NCT00030667 - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Phase 2
Active, not recruiting NCT03108677 - Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma
Withdrawn NCT01325753 - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body N/A
Recruiting NCT05755672 - On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
Active, not recruiting NCT01706432 - Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Not yet recruiting NCT04888806 - A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis Phase 2
Recruiting NCT06321640 - Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Completed NCT02496585 - Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis Phase 2
Withdrawn NCT01741597 - Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Phase 1
Completed NCT01621698 - Study of Use of Paravertebral Blocks for Pain Relief in Video Assisted Lung Surgery N/A
Terminated NCT01258634 - A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response Phase 1
Active, not recruiting NCT02226276 - Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer N/A